Celera unveils immunotherapeutic programs

On a joint conference call discussing earnings for CRA and sister company Applied Biosystems (ABI, see above), CRA President Craig Venter said the company has begun its first two immunotherapeutic programs - in lung and pancreatic cancer.

CRA estimated it would spend $205-$220 million on R&D in the fiscal year ending June 30, 2002. That excludes an estimated $55-$65 million it plans to spend on its recently announced Celera Diagnostics joint venture with ABI (see BioCentury Extra, Tuesday June 25). CRA spent $207.7 million on R&D in the year ended June 30. ...